Beacon Biosignals participated in SLEEP 2026, eng
Author: Michael
Greenstone Biosciences, Inc. and Intel Corp.
Positive Phase 1b results for ATX-304 suggest sc
Positive Phase 1b results for ATX-304 suggest sc
Phase 2 trial of leramistat targets sarcopenia,
Australian healthtech Everlab has raised $42 mil
New funding will support development of regenera
Stress-enduring cells offer a precision, homing-
Insilico Medicine announced completion of first-i
Oligomerix has received a $1.